Literature DB >> 15115400

Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.

David R Magnin1, Jeffrey A Robl, Richard B Sulsky, David J Augeri, Yanting Huang, Ligaya M Simpkins, Prakash C Taunk, David A Betebenner, James G Robertson, Benoni E Abboa-Offei, Aiying Wang, Michael Cap, Li Xin, Li Tao, Doree F Sitkoff, Mary F Malley, Jack Z Gougoutas, Ashish Khanna, Qi Huang, Song-Ping Han, Rex A Parker, Lawrence G Hamann.   

Abstract

A series of methanoprolinenitrile-containing dipeptide mimetics were synthesized and assayed as inhibitors of the N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV). The catalytic action of DPP-IV is the principle means of degradation of glucagon-like peptide-1, a key mediator of glucose-stimulated insulin secretion, and DPP-IV inhibition shows clinical benefit as a novel mechanism for treatment of type 2 diabetes. However, many of the reversible inhibitors to date suffer from chemical instability stemming from an amine to nitrile intramolecular cyclization. Installation of a cyclopropyl moiety at either the 3,4- or 4,5-position of traditional 2-cyanopyrrolidide proline mimetics led to compounds with potent inhibitory activity against the enzyme. Additionally, cis-4,5-methanoprolinenitriles with beta-branching in the N-terminal amino acid provided enhanced chemical stability and high inhibitory potency. This class of inhibitors also exhibited the ability to suppress prandial glucose elevations after an oral glucose challenge in male Zucker rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115400     DOI: 10.1021/jm049924d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.

Authors:  Norikazu Sakakibara; Masanori Baba; Mika Okamoto; Masaaki Toyama; Yosuke Demizu; Takashi Misawa; Masaaki Kurihara; Kohji Irie; Yoshihisa Kato; Tokumi Maruyama
Journal:  Antivir Chem Chemother       Date:  2015-02

3.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Authors:  Koen Jansen; Leen Heirbaut; Jonathan D Cheng; Jurgen Joossens; Oxana Ryabtsova; Paul Cos; Louis Maes; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2013-03-18       Impact factor: 4.345

4.  Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4.

Authors:  Yongliang Gu; Wei Wang; Xiaolei Zhu; Keke Dong
Journal:  J Mol Model       Date:  2014-01-31       Impact factor: 1.810

5.  New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.

Authors:  Baptist Gallwitz
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

6.  Fluorocyclopropane-Containing Proline Analogue: Synthesis and Conformation of an Item in the Peptide Chemist's Toolbox.

Authors:  Amandine Pons; Jonathan Decaens; Riham Najjar; Nansalmaa Otog; Mathieu Arribat; Sandrine Jolly; Samuel Couve-Bonnaire; Muriel Sebban; Gael Coadou; Hassan Oulyadi; David Speybrouck; Seiji Iwasa; André B Charette; Thomas Poisson; Philippe Jubault
Journal:  ACS Omega       Date:  2022-02-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.